Option Writers Newsletter, Tuesday, 01/25/2005 05:41:12 PM ET
HAVING TROUBLE PRINTING?
LCAV - LCA-Vision $25.30
LCA-Vision (NASDAQ:LCAV) is a developer and operator of
fixed-site, laser vision correction centers under the brand
name LasikPlus. The company's vision centers provide the
staff, facilities, equipment and support services for
performing laser vision corrections that employ advanced
laser technologies to help correct nearsightedness,
farsightedness and astigmatism.
LCA utilizes fixed-site excimer lasers manufactured by
Bausch & Lomb, VISX and Alcon. Its vision centers are
supported by full-time, board-certified ophthalmologists,
optometrists, and other healthcare professionals. The
ophthalmologists perform the laser vision correction
procedures in the company's vision centers, and either
ophthalmologists or optometrists generally carry out the
pre-procedure evaluations and post-procedure follow-ups.
LCAV shares were one of the big "percentage gainers" on
the NASDAQ today and the stock also topped our list of
(technically) bullish issues. There was little public news
to explain the upside move, however the trading volume
speaks "buy" loud and clear. With earnings (apparently)
due in mid-February, there is plenty of time to build in a
reasonable downside margin and the trading-range "top"
near $23.50 should now provide a substantial level of
support for any near-term consolidation. Speculation Only!
Sell Put FEB 22.50 JVQ-NX
Current Bid = $0.55 Open Interest = 223
Potential Profit (5 contracts) = $275
Initial Margin (5 contracts) = $3,935
Return on Investment (max) = 8.9%
Cost Basis in Stock = $21.95
Days to Expiration = 24